Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its first quarter ending March 31, 2024.

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $8.84, denoting a +0.57% change from the preceding trading day.

Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know

Zacks.com users have recently been watching Recursion Pharmaceuticals (RXRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know

SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its first quarter 2024 financial results on Thursday, May 9, 2024, following the close of the financial markets. Additionally, Recursion will host its quarterly L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.

Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9

SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences:

Recursion to Participate in Upcoming Investor Conferences

NVIDIA

Nvidia's equity portfolio ballooned beyond $100 million in the fourth quarter, requiring public disclosures. Just two stocks make up nearly all of its portfolio.

Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves

Exelixis

Iovance Biotherapeutics

Biotech stocks are notorious for being some of the most volatile and unpredictable on the market. With clinical trials and FDA approvals creating potential leaps or falls in what seems like an instant, there is no denying the risk involved.

The Top 3 Biotech Stocks to Buy in April 2024

Recursion Pharmaceuticals (RXRX) closed at $7.84 in the latest trading session, marking a -1.26% move from the prior day.

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors

Viking Therapeutics

Oncology's future prominently features the kind of autoimmune R&D work that Iovance is doing. Helped by new technology, Recursion is using artificial intelligence to develop new drugs.

3 Millionaire-Maker Biotech Stocks

Sana Biotechnology

Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent, a CDMO organization.

Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX

By 2029, Recursion Pharmaceuticals could have multiple products. There is also a chance it could be facing some serious challenges.

Where Will Recursion Pharmaceuticals Be in 5 Years?

Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of Directors Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of Directors

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Actinium Pharmaceuticals

CorMedix

Fulcrum Therapeutics Inc

Marinus Pharmaceuticals

Ocular Therapeutix

Outlook Therapeutics Inc

The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

Coinbase

Nextdoor

Known for her focus on innovative disruption, Cathie Wood has become one of the biggest names in capital management. With her firm, ARK Invest, Wood has created custom exchange-traded funds focused on aggregating high-potential stocks.

Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good.

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.

Ginkgo Bioworks Holdings

Effective use of AI could lead some biopharmas to outperform. Ginkgo Bioworks integrates AI into multiple layers of its business model.

The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation

Recursion Pharmaceuticals' approach to developing drugs is ambitious. But the company has yet to produce the kinds of results investors want.

Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?

Recursion Pharmaceuticals (RXRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround

Recursion Pharmaceuticals (RXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy

Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact. Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact.

Recursion Publishes Annual Environmental, Social and Governance Report

SoundHound AI Inc

ARM Holdings PLC

Nano-X Imaging

Following Nvidia's investment disclosure, SoundHound AI's shares have dramatically increased, tripling in value and boosting its market capitalization to $2.75 billion. The company's success is attributed to its innovative AI voice technology used across various industries, from fast-food to automotive.

Not just Soundhound, these AI stocks are also riding Nvidia wave

Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the heart of King's Cross neighborhood Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the heart of King's Cross neighborhood

Recursion Announces Plans to Open New Office in London

The company just took full control of one of its collaborations with Bayer. It'll take a long time for this play to demonstrate any value.

Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst

SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, hosted its second annual Rare Disease Day event at its headquarters on February 29 and virtually in partnership with Alliance to Cure at eight sites across the United States to provide resources and support for Utah's rare disease community. The event featured speakers from patient advocacy organizations and biotech and healthcare industry leaders who all share a goal to accelerate the diagnosis and improve the care of more than 344,000 Utahns living with a rare disease.

Recursion Hosts Second Annual Rare Disease Day Events for Utah's Rare Disease Community

Prime Medicine Inc

10X Genomics

The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime.

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?

News for Recursion Pharmaceuticals Stock (RXRX)